Abstract
Introduction High-dose vitamin C (hdVC) is regarded as one of the essential adjunctive drugs for sepsis treatment. The present study aimed to deduce if hdVC could lead to erroneous testing results from the point-of-care glucose (POCG) measurement.
Methods and materials This retrospective, single-center, observational case series involved septic patients treated by hdVC and monitored their paired POCG and laboratory glucose (LG) level for statistical analysis. The Parkes Consensus Error Grid Analysis was used as clinical influence assessment for paired blood glucose values. Subgroup analyses were conducted to explore the affecting extent of POCG readings by different VC dosage and various renal function level respectively.
Results During the 3-year research period, 82 eligible septic patients who accepted at least three-day hdVC treatment were included in the current study. Compliance with ISO15197:2013 criteria was met in 30 (36.59%) paired values, which was far from the minimum criteria for accuracy. Subgroup analysis showed that worse renal function or higher VC dosage could lead to greater bias of POCG reading, but clinical risk would come forth scarcely while dealing with inaccurate POCG value.
Conclusions High-dose intravenous ascorbate acid infusion could interfere POCG measurement values and LG method is more recommended, although significant medical risk hardly appears when physicians alter clinical action based on unreliable POCG reading.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Shanghai Shen Kang Hospital Development Center Clinical Science and technology innovation project (No. SHDC12017116) and Important and weak discipline construction plan for health and family planning system of Shanghai (No. 2016ZB0206).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Ruijin Hospital Institutional Review Board and has been performed in accordance with the ethical standards laid down in Declaration of Helsinki 1964 and its later amendments or comparable ethical standards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
